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Abstract
Resistance of transplanted mesenchymal stem cells (MSCs) in post-ischemic heart is limited by their poor vitality. Vascular-endothelial-growth-
factor-A (VEGF-A) as such or slowly released by fibronectin-coated pharmacologically-active-microcarriers (FN-PAM-VEGF) could differently
affect survival kinases and anti-apoptotic mediator (e.g. Bcl-2). Therefore VEGF-A or FN-PAM-VEGF could differently enhance cell proliferation,
and/or resistance to hypoxia/reoxygenation (H/R) of MSCs. To test these hypotheses MSCs were incubated for 6-days with VEGF-A alone or
with FN-PAM-VEGF. In addition, MSCs pre-treated for 24-hrs with VEGF-A or FN-PAM-VEGF were subsequently exposed to H/R (72-hrs 3% O2
and 3-hrs of reoxygenation). Cell-proliferation and post-hypoxic vitality were determined. Kinases were studied at 30-min., 1- and 3-days of
treatment. Cell-proliferation increased about twofold (P < 0.01) 6-days after VEGF-A treatment, but by a lesser extent (55% increase) with FN-
PAM-VEGF (P < 0.05). While MSC pre-treatment with VEGF-A confirmed cell-proliferation, pre-treatment with FN-PAM-VEGF protected MSCs
against H/R. In the early phase of treatments, VEGF-A increased phospho-Akt, phospho-ERK-1/2 and phospho-PKCe compared to the untreated
cells or FN-PAM-VEGF. Afterword, kinase phosphorylations were higher with VGEF, except for ERK-1/2, which was similarly increased by both
treatments at 3 days. Only FN-PAM-VEGF significantly increased Bcl-2 levels. After H/R, lactate dehydrogenase release and cleaved Caspase-3
levels were mainly reduced by FN-PAM-VEGF. While VEGF-A enhances MSC proliferation in normoxia, FN-PAM-VEGF mainly hampers post-hyp-
oxic MSC death. These different effects underscore the necessity of approaches suited to the various conditions. The use of FN-PAM-VEGF
could be considered as a novel approach for enhancing MSC survival and regeneration in hostile environment of post-ischemic tissues.
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Introduction
In spite of the beneficial effects observed in cell therapy after myocar-
dial infarction, retention, survival and functionality of transplanted
cells still need to be improved. Many investigators attempted to mod-
ify the ratio ‘organ tissue damage/repair’ by means of stem cell-based
regenerative therapies during the last decade [1, 2]. Results from
recent clinical studies with infarcted patients showed improved car-
diac function following injection of adult stem cells from different
sources including bone marrow and peripheral blood [2–4]. Mesen-
chymal stem cell (MSCs) transplantation is a promising strategy.
However, cell replacement therapy is limited by the poor vitality of
transplanted MSCs, especially in hypoxic environment [5, 6].
It has been reported that the capacity of transplanted bone mar-
row MSCs to survive and subsequently integrate into host heart may
be so poor that about 99% of transplanted cells are lost during the
first 24-hrs after transplantation [6, 7]. In fact, after infusion or injec-
tion into an ischemic tissue, MSCs face a hostile, inflammatory envi-
ronment that may strongly limit their function and survival. Another
important process to be considered during the implantation of MSCs
in the injured organ is the formation of new vasculature. In fact, it is
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necessary that during the repair of the ischemic tissue an appropriate
angiogenesis occurs [8].
Experimental observations have shown the plasticity of bone
marrow MSCs indicating that in appropriate conditions these cells
can repair a damaged tissue [2, 9]. The influence of endogenous
factors such as cytokines, growth factors, and the local cellular
milieu upon MSCs remains poorly understood [10–17]. Members
of the vascular endothelial growth factor (VEGF) family and their
receptors (VEGFR) play important roles in the development and
maintenance of the blood and lymphatic vasculature. To date, five
VEGFs have been identified in the mammalian (VEGF-A, -B, -C, -D,
and placental growth factor), which display distinct binding affini-
ties for VEGFR-1, -2, and -3. Several isoforms of VEGF-A (mainly
VEGF121, VEGF165 and VEGF189) have been shown to display angio-
genic properties [18]. In particular, in the brain, vessel formation
after VEGF-A exposure has been observed already after 4 days
[19].
Besides being a promoter of angiogenesis, VEGF-A, is consid-
ered a multifunctional growth factor; in particular, it promotes
myocardial protection in the short term by decreasing cardiomyo-
cyte apoptotic signaling and in the long term by increasing neovas-
cularization and tissue perfusion [20, 21]. Bone marrow MSCs
themselves are capable of producing VEGFs both in normo- and in
hypoxic-conditions [22]. However, evidently, this production is not
enough to promote their protection when transplanted [5–7]. Exog-
enous VEGF-A can directly augment myocardial function during
acute ischemia/reperfusion [23]. Moreover, VEGF-A can induce the
activation of survival protein kinases including Akt pathway, as well
as the activation of antiapoptotic and growth/hypertrophy signaling
pathways [24, 25]. Accordingly, one would expect that VEGF-A may
increase the progeny formation of MSCs. However, the size of pro-
genitor-cell compartment is governed by the balance between the
cell gain (self renewal) and the cell loss (apoptosis, necrosis).
Therefore, an imbalance in renewal and apoptosis will result in
an elevation or a fall in the progenitor cell mass [26]. It can be
expected that the limitation of cell death in a hostile environment
may require a prolonged activity of the protective agent. Since
VEGF-A may affect both self renewal and apoptosis, and since
pharmacologically-active-microcarriers (fibronectin-coated poly(lac-
tic-co-glycolic acid (PLGA) microcarriers containing VEGF-A; FN-
PAM-VEGF) have been developed, which allow in situ prolonged/
controlled VEGF-A delivery and cell adhesion by their fibronectin
biomimetic surface, we hypothesize that there are substantial differ-
ences on MSC survival depending on whether this growth factor is
applied as a free compound or incorporated within FN-PAMs for a
sustained release. Moreover, it is important to note that this
approach combines the effect of the controlled release of VEGF-A to
the 3D biomimetic support provided by the FN-PAMs. Indeed, it has
been shown that FN and a 3D support together or separately stimu-
late survival of MSCs [27].
This would be consistent with studies which already used gelatin,
PLGA and alginate microspheres as a biocompatible polymeric
support for the controlled release of bioactive VEGF-A in vivo [27–29].
In the present study we compared in vitro whether or not
FN-PAMs delivering VEGF165 (FN-PAM-VEGF) induce a different
protective/proliferative effects compared to VEGF165 alone. In
particular, we tested whether MSC survival in hypoxic conditions
is differently influenced by FN-PAM-VEGF and VEGF165 pre-
treatment.
Materials and methods
Unless otherwise specified, reagents were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Tissue culture plasticware was obtained
from M-Medical (Milan, Italy).
Formulation of PAMs Releasing VEGF165
Poly(lactic-co-glycolic acid) (PLGA)-microspheres of an average diame-
ter of 60 lm were prepared using an emulsion solvent extraction-evap-
oration process previously described [28]. The PLGA-copolymer is with
a lactic:glycolic ratio of 37.5:25 (MW: 25,000 D; Phusis, Saint Ismier,
France). The total protein loading was 0.6% w/w with respect to the
amount of polymer, i.e. 0.1% VEGF165 and 0.5% HSA.
The used VEGF165 is a recombinant VEGF-A (Peprotech, Neuilly-Sur-
Seine, France), and to simplify the reading, hereafter we referred to
VEGF-A when it is used alone and to VEGF when it is used in com-
posed words. First, NaCl and glycofurol, a water-miscible non-solvent
of proteins, were used to precipitate the proteins separately, as previ-
ously described [30] and adapted to each protein. For VEGF-A a NaCl
solution at 0.01 M at 4°C, containing a protein-poloxamer 188 excipi-
ent in an additive to protein ratio of 20:1 was added and mixed to gly-
cofurol to form a 1 ml suspension. The same procedure was used for
HSA with a NaCl solution at 0.3 M. Thirty minutes later, the protein
nanoparticles were recovered by centrifugation (10,000 g, 30-min.).
They were then carefully dispersed in the organic solution (667 ll; 3:1
methylene chloride:acetone) containing 50 mg polymer and emulsified
in a poly (vinyl alcohol) aqueous solution (90 ml, 4% w/v) maintained
at 1°C and mechanically stirred for 1-min. (Heidolph RZR2041, Merck
Eurolab, Paris, France). After addition of 33 ml of deionized water and
stirring for 10-min., the resulting o/w emulsion was added to deion-
ized water (167 ml) and stirred at 550 r.p.m. further for 20-min. to
extract the organic solvent. Finally, the formed microparticles were fil-
tered on a 5 lm filter (HVLP type, Millipore SA, Guyancourt, France),
washed with 500 ml of deionized water and freeze-dried. Unloaded mi-
croparticles were prepared in the same manner without adding the
protein.
The microspheres were coated with 12 lg/ml of poly-D-lysine and
18 lg/ml of fibronectin (Sigma-Aldrich, Saint-Quentin Fallavier, France)
as previously describes [31]. Briefly, microspheres were placed under
rotation with the fibronectin-poly-D-lysine mixture for 90-min. at
15 r.p.m. in an incubator and were then freeze-dried and stored at 4°C
for the experiments or immediately used for release kinetics studies.
These fibronectin-coated microspheres are named FN-PAMs.
Protein encapsulation efficiency
Protein encapsulation yield was determined considering both the VEGF-
A biologically active entrapped protein and the total protein. Protein
PLGA microspheres (5 mg) were dissolved in 1 ml acetone in silanized
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glass tube for 1 hr, the entrapped protein was separated from the dis-
solved polymer by centrifugation (15-min., 14,662 g) and the acetone
was removed. To ensure that the entire polymer was dissolved, 1 ml of
acetone was added and the solution was left to stand for one more
hour, and then totally removed after centrifugation (15-min., 14,662 g).
The pellet was resuspended in PBS. The encapsulation efficiency was
measured using a protein dosage kit, NanoOrange test (Invitrogen,
Cergy-Pontoise, France) and VEGF ELISA kits (Peprotech).
Release kinetics, in vitro study
The in vitro release profile of protein from PLGA microspheres was
determined by adding 250 ll of PBS buffer, pH 7.4, containing 1% w/v
BSA to 2.5 mg of FN-PAM-VEGF into eppendorf tubes. The tubes were
closed and incubated in a shaking water bath (37°C, 125 r.p.m.). The
tubes were centrifuged for 5-min. at 664 g and 250 ll of the superna-
tant were collected for analysis and replaced by fresh buffer. This
procedure was repeated at different time-points (1, 2, 3, 4, 7, 10, 14
and 21 days) and the released VEGF-A present in the collected aliquots
was measured by ELISA (Peprotech). The theoretical amount of VEGF-A
present in the 2.5 mg FN-PAM-VEGF was corrected using the results of
the encapsulation yield allowing the actual amount of VEGF-A contained
in the FN-PAM-VEGF to be established. The cumulative release of VEGF-
A over time was then calculated.
To confirm the biological activity of the released VEGF-A a bio-
assay was performed using a human umbilical vein endothelial
cells (HUVECs; Lonza, Warkerville, MD, USA) proliferation assay;
HUVECs were cultured and passaged in standard endothelial cell
medium (EGM-2 medium; Lonza) which includes a supplement of
growth factors. The HUVECs were then plated (5 9 103 cells) onto
24 well plates, with filtered medium (supplement-free). On these
HUVECs proliferation was first investigated by the Alamar Blue
assay (Invitrogen) using different concentrations of free VEGF-A at
24-hrs, 48-hrs, 5-days and 1-week time-points; the best effect
was observed with 4 ng/ml VEGF-A for 5-days. Over a period of
5-days HUVEC proliferation was then investigated using the sam-
ples collected from FN-PAM-VEGF under the same conditions per-
formed to evaluate the release kinetics of VEGF-A and at the time-
points above reported. Each sample was diluted to 4 ng/ml of
released VEGF-A, according to the ELISA results, and compared to
the supplement-free medium alone or supplement-free medium
containing 4 ng/ml of free VEGF-A.
MSC isolation and cell culture
Mesenchymal stem cells were extracted from bone marrow of femurs
of Wistar rats 6–12 months of age (weight 450–550 g; Janvier, Le
Genest St Isle, France). MSCs were extracted by inserting a 21-gauge
needle into the shaft of the bone and flushing with a solution of mini-
mum essential medium eagle a (a-MEM) and 20% fetal bovine serum
(FBS) (Sigma-Aldrich, Milan, Italy) implemented with 2 mM glutamine,
100 U/ml penicillin and 100 mg/ml streptomycin (Lonza); the cell sus-
pension was filtered and cultured at 37°C. After 24-hrs the medium was
replaced with a-MEM containing 10% FBS, 2 mM glutamine, 100 U/ml
penicillin and 100 mg/ml streptomycin. We allowed MSCs to grow up
to passage 3 (P3), replacing the medium every 2–3 days as reported in
the literature [32–35].
To verify that the cell population we used for cultures was composed
of MSCs, we showed that the cells were CD90 positive and CD34/CD45
negative [32–34]. Moreover, previous differentiation experiments
performed in our laboratories showed the MSC potential to differentiate
into adipocytes [34], osteoblasts and muscle cells [32]. The MSCs were
then included in the study and used accordingly to the protocols
described below.
Rats were used in accordance with the Italian law (DL-116, 27 Janu-
ary 1992) and the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH Publication no.
85-23, revised 1996). The project was approved by the Italian Ministry
of Health, Rome, and by the ethics review board of the University of
Turin. Rats were anesthetized by i.p. injection of urethane (1 g/kg) and
killed by decapitation [35].
MSC adhesion to microspheres
FN-PAMs and FN-PAM-VEGF were used according to the following pro-
tocol: 0.5 ml of a-MEM with 10% FBS was added into the eppendorf
containing the microspheres (0.5 mg) and incubate for 15-min. in order
to resuspend them. Just before cell attachment, the solution containing
microspheres was vortexed, put in an ultrasound bath for 30-sec. and
vortexed again. Pilot experiments confirmed that this procedure avoids
possible FN-PAM-aggregates; thus providing the largest surface for
MSC adhesion, without affecting microsphere integrity. Then the micro-
sphere suspension was put into ultra low attachment cluster plates
(Corning, Sigma-Aldrich, Milano, Italy) and 9.0 9 104 MSCs in 0.5 ml
of culture medium were added.
Normoxic and hypoxic experimental conditions
(1) Normoxia: i.e. standard conditions (normoxic: 21% O2 and 5%
CO2) to study cell survival; these gas concentrations are identical to
those used during MSC culture from isolation to P3.
(2) Hypoxia/reoxygenation (H/R): i.e. hypoxic mixture (3% O2 and 5%
CO2) for 72-hrs and subsequent reoxygenation (21% O2 and 5% CO2)
for 3-hrs to study cell survival.
Study of viability in standard-normoxia with and without
treatment with VEGF-A, FN-PAMs or FN-PAM-VEGF
We carried out experiments with MSCs exposed to agents for 3 or
6 days (Fig. 1). Therefore the groups considered in this study were the
following:
(i) Control: MSCs were kept under standard conditions for 3-days
(MSC-3) or 6 days (MSC-6);
(ii) FN-PAMs: 0.5 mg FN-PAMs were added to culture medium
together with 9.0 9 104 MSCs and kept under standard conditions for
3-days (FN-PAM-3) or 6-days (FN-PAM-6);
(iii) FN-PAM-VEGF: 0.5 mg VEGF/FN-PAM were added to culture med-
ium together with 9.0 9 104 MSCs and kept under standard conditions
for 3-days (FN- PAM-VEGF-3) or 6-days (FN-PAM-VEGF-6);
(iv) VEGF-A: 9.0 9 104 MSCs were cultured and kept under standard
conditions, and then VEGF-A (9 ng) was added to the cell culture for 3-
days (VEGF-3) or 6-days (N-VEGF-6).
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Study of survival after H/R with and without pre-treatment
with VEGF-A, FN-PAMs or FN-PAM-VEGF
In this protocol, experiments were carried out with MSCs alone or
MSC pretreated with the studied factors (FN-PAMs, FN-PAM-VEGF or
VEGF-A; Fig. 2). In particular, the MSCs were pre-treated with VEGF-A
(9 ng), FN-PAMs (0.5 mg) or FN-PAM-VEGF (0.5 mg) for 24-hrs.
Before exposure to hypoxic condition, MSCs were incubated with
trypsin-EDTA 0.25% solution and subjected to mild centrifugations
(250–300 g for 5-min.) in order to separate cells from FN-PAMs or
FN-PAM-VEGF. Then the medium was changed and cells were cul-
tured in 2% FBS without treatment factors. Thereafter, subgroups of
cells were subjected to a protocol of hypoxia/reoxygenation (72/3 hrs)
in a hypoxic chamber (INVIVO2 200, Belsar, Varese, Italy). Therefore
the groups considered in the study of cell survival were the following:
(i) Untreated MSCs kept under standard conditions for 3-days (MSC-
3-N), and untreated MSCs exposed to H/R (MSC-3-H);
(ii) MSCs pre-treated with FN-PAM and kept under standard condi-
tions (FN-PAM-3-N), and MSCs pre-treated with FN-PAMs and exposed
to H/R (FN-PAM-3-H);
(iii) MSCs pre-treated with FN-PAM-VEGF and kept under standard
conditions (FN-PAM-VEGF-3-N), and MSCs pre-treated with FN-PAM-
VEGF and exposed to H/R (FN-PAM-VEGF-3-H);
(iv) MSCs pre-treated with VEGF-A and kept under standard condi-
tions (VEGF-3-N), and MSCs pre-treated with VEGF-A and exposed to
H/R (VEGF-3-H).
In brief, in each of the above four groups, for comparative purpose
we considered normoxic (-N) and hypoxic (-H) protocols.
Cell survival
At the end of experiments cell survival was assessed using the cell via-
bility test 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay (Sigma-Aldrich, Italy) [36]. The release of lactate dehydro-
genase (LDH) was also checked at the beginning of the experiments
and after 3- or 6-days using a dedicated assay (Sigma-Aldrich, Italy)
[37].
Western blotting
In order to compare the effects of FN-PAM-VEGF and VEGF-A on criti-
cal proteins for cell survival and apoptosis, the analysis of western
blotting was performed on MSCs exposed to normoxic conditions after
30-min., 1- and 3-days of treatment; the analysis was also performed
after exposure of MSCs to H/R conditions (see upward arrows of
Figs 1 and 2).
About 50 lg of protein extracts were separated by SDS-10% PAGE
and transferred to PVDF membranes (GE Healthcare, VWR, Milan, Italy).
The membranes were incubated overnight with the following antibodies:
anti-Akt (Cell Signaling, Euroclone, Pero (MI), Italy), anti-PKCe (Cell
Signaling), anti-ERK1/2 (Cell Signaling), anti-Bcl-2 (Cell Signaling) and
anti-cleaved Caspase-3 (Cell Signaling), and phosphorylated forms anti-
phospho-Akt (Ser 473, Cell Signaling), anti-phospho-PKCe (Ser 729,
Upstate, Prodotti Gianni, Milan, Italy) and anti-phospho-ERK1/2 (Thr
402-Tyr 204, Cell Signaling). All antibodies were diluted according to
manufacturer’s instructions. Western blotting analysis was displayed by
the Immuno-Star HRP substrate (BioRad, Segrate (MI), Italy) and quan-
tified by Kodak Image Station 440CF. The quantification of protein used
Study of viability in standard-normoxia
0
MSC-3
MSC-6
FN-PAM-3
FN-PAM-6
FN-PAM-VEGF-3
FN-PAM-VEGF-6
VEGF-6
VEGF-3
1 2 3 4 5 6 Days
Fig. 1 Time-lines and protocols for experimental groups in normoxia.
Timing of various interventions is shown in relation to the onset of cell
culture. Mesenchymal stem cells (MSCs) were kept under
standard-normoxia conditions for 3- or 6-days (MSC-3 or MSC-6).
Fibronectin-coated pharmacologically-active-microcarriers (FN-PAM),
FN-PAM incorporating VEGF-A (FN-PAM-VEGF) or free VEGF-A were
added at time 0, and after 3-days for the 6-days groups. Assessments
were performed after 30-min. from the beginning of treatments and
then 1-, 3- and 6-days after (upwards arrows). For other acronyms see
also the text.
Study of survival after hypoxia/reoxygenation
Pre-treatment
–1
MSC-3-N
MSC-3-H
FN-PAM-3-N
FN-PAM-3-H
FN-PAM-VEGF-3-H
FN-PAM-VEGF-3-N
VEGF-3-N
VEGF-3-H
0 1 2 3
3
hrs
Hypoxic condition
(3% O2 and 5% CO2)
Normoxic condition
(21% O2 and 5% CO2)
21
Days
Fig. 2 Time-lines and protocols for experimental groups in hypoxia/reox-
ygenation. Timing of various interventions is shown in relation to the
onset of cell culture. Mesenchymal stem cells (MSCs) were kept under
standard conditions for 1-day, then they were subjected to 3-days
hypoxia and 3-hrs reoxygenation. Fibronectin-coated pharmacologically-
active-microcarriers (FN-PAM), FN-PAM incorporating VEGF-A (FN-PAM-
VEGF) or free VEGF-A were added at time 0. For comparative purpose
we considered normoxic (-N) and hypoxic (-H) protocols. Assessments
were performed after 30-min. from the beginning of treatments and
then before and after hypoxia, and at the end of reoxygenation
(upwards arrows). For other acronyms see also the text.
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was performed according to Bradford method [38]. The image analysis
was performed using the Kodak 1D 3.5 software [39].
To confirm that equal amounts of protein were loaded membranes
were incubated with anti-b actin (Sigma-Aldrich, Italy). For each condi-
tion, we normalized the expression of kinases to its matched loading
control b actin and then to the mean values of MSC-3.
Statistical analysis
Data were expressed as mean ± SEM and reported as percentage of
control. The values were analyzed using ANOVA and Newman-Keuls Mul-
tiple Comparison Test as post-ANOVA test, and were considered signifi-
cant for P < 0.05.
Results
VEGF-A encapsulation and release kinetics from
FN-PAM-VEGF
The encapsulation yield of total protein into FN-PAM-VEGF was
67.8% and was 59.4% of biologically active VEGF-A. A nice con-
tinuous release of VEGF-A from these PAMs was observed for at
least 3 weeks consisting in a cumulative release of 300 ng/ml for
2.5 mg FN-PAM-VEGF and representing 21% of the entrapped
protein (Fig. 3). The VEGF-A collected from each sample of the
kinetic release assay (diluted to 4 ng/ml) was able to stimulate
HUVEC proliferation for a period of 5-days in a similar manner
as the free VEGF-A at 4 ng/ml (data not shown). The bioassay
performed with the HUVEC cells confirmed that the VEGF-A was
released under a bioactive conformation during the entire period.
One milligram FN-PAM was loaded with 1.0 lg VEGF-A. Based
on the release kinetics study of VEGF-A, FN-PAM-VEGF released
17.8 ng VEGF-A/mg FN-PAM/day during the first week. Since we
used 0.5 mg of FN-PAM-VEGF, the dose of VEGF-A was about
9 ng/day. Therefore, the doses of VEGF-A employed in the two
conditions with the cells (FN-PAM-VEGF or VEGF-A only) are
identical. This concentration of VEGF-A is similar (nanomolar
range) to that used in other cellular models (explants of cerebral
cortex) [40] and in the MSC in vitro [41].
Cell proliferation analysis in normoxic conditions
In Figure 4, data are presented as percent variation with respect to
mean value of cell count in control (MSC-3). We found that there were
no significant differences in cell viability between MSC and FN-PAM
groups both after 3 and 6 days.
The treatment for 3-days in FN-PAM-VEGF-3 and VEGF-3
groups did not induce significant variations in cell viability with
respect to MSC-3. However after 6-days, both VEGF-6 and FN-
PAM-VEGF-6 increased significantly cell viability with respect to all
other conditions (P < 0.01 and P < 0.05, respectively; Fig. 4). In
particular, compared to control cell numbers were increased by FN-
PAM-VEGF-6 and even more by VEGF-6 (+155 ± 6% and
+216 ± 4%, respectively).
While after 3-days LDH increase was not significant with respect
to baseline level, it was significantly increased after 6-days treatment
(Fig. 5). Since similar LDH release occurred among all groups after
3- and 6-days, i.e. no difference in cell death was observed through-
out the experiments, the differences in cell number (Fig. 4) are likely
due to different cell proliferation. These results suggest that VEGF-A
has a more potent proliferative effect than FN-PAM-VEGF after 6 days
of treatment in normoxia.
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Fig. 3 Illustrative release kinetics of VEGF-A from fibronectin-coated
pharmacologically-active-microcarriers complexed with VEGF-A (FN-
PAM-VEGF) and bioassay. The cumulative release of VEGF-A from FN-
PAM up to 4 weeks was 21% that represent about 300 ng/ml of the
entrapped protein. Each point represents the mean of triplicate experi-
ments. The release profile was performed with 2.5 mg PAMs. VEGF-A
collected from each sample of the release kinetics assay was able to
stimulate HUVEC proliferation as an equal amount of native VEGF-A for
a period of 7 days (data not shown).
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Fig. 4 Cell growth in normoxia with and without factors (free-VEGF-A,
FN-PAMs or FN-PAM-VEGF) after 3 and 6 days. Data are% variation
with respect to mean value of MSCs kept under standard conditions for
3-days (MSC-3). After 3-days treatment there are not statistical differ-
ences among groups. After 6-days treatment cell growth was signifi-
cantly increased by FN-PAM-VEGF-6 and even more by VEGF-6.
*P < 0.05 versus other groups; **P < 0.001 versus all other groups.
n = 5 for each condition.
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Survival analysis after H/R in pretreated cells
In Figure 6, data are presented as percent variation with respect to
mean value of cell count in control conditions (MSC-3-N). The analy-
sis of viability in normoxia showed that 24-hrs pre-treatment with
either FN-PAMs or FN-PAM-VEGF did not influence cell numbers;
however, VEGF-A pretreatment (VEGF-3-N) increased cell number.
These data support the idea that free-VEGF-A has a major pro-prolif-
erative effect.
In the absence of pre-treatment, the H/R protocol induced a 34%
reduction in MSC number (P < 0.01, MSC-3-N versus MSC-3-H).
Also in MSCs pretreated with empty FN-PAMs a similar percent
reduction (27%) of cells was observed (P < 0.05, FN-PAM-3-N ver-
sus FN-PAM-3-H). However the pre-treatment with FN-PAM-VEGF
preserved cell survival and was able to counteract hypoxia effects
(P = not significant between FN-PAM-VEGF-3-N and FN-PAM-VEGF-
3-H), yet pre-treatment with free VEGF-A was not able to preserve
survival; in fact a 38% reduction in MSC number was observed in
VEGF-3-H (P < 0.01 versus VEGF-3-N). LDH data corroborated these
results (data not shown).
These results suggest that pre-treatment with FN-PAM-VEGF lim-
its cell mortality after H/R.
Western Blot analysis
Analysis in normoxic conditions
Figures 7–9 show the total and phospho-kinase bands (central pan-
els) with relative normalized ratio (left panels) and mean values of
normalized phospho-enzyme levels (right panels), assessed after 30-
min., 1- and 3-days of treatment, respectively. In these figures (A)
MSC control group, (B) MSC treated with FN-PAM-VEGF, and (C)
MSC treated with free-VEGF-A.
As can be seen in Figure 7, after 30-min. treatment with VEGF-A
there was an increase in Akt, ERK 1/2 and PKCe phosphorylation [24,
25]. On the contrary, FN-PAM-VEGF, which slowly releases VEGF-A
(see Fig. 3), does not influence kinase phosphorylation.
After 1 day treatment (Fig. 8), kinase phosphorylations
observed at 30-min. in VEGF-A group are no longer present. More-
over, FN-PAM-VEGF induces a significant reduction in phospho-Akt
levels. Starting from different levels of total kinases, after 3-days
(Fig. 9) the phospho-Akt and phospho-PKCe abundances were still
reduced, but more with FN-PAM-VEGF than with free VEGF-A. In
particular, the analysis for Akt (Top Panels) evidenced a reduced
phospho/total ratio of Akt in FN-PAM-VEGF and a preserved ratio in
VEGF-A only. The level of phospho-Akt was lower in treated groups
(both VEGF-A and FN-PAM-VEGF). Importantly, phospho-Akt level
was higher in VEGF-A than in FN-PAM-VEGF group. Also the analy-
sis for PKCe (Bottom Panels) evidenced an increased phospho/total
ratio in both FN-PAM-VEGF and VEGF-A; however phospho-PKCe
level resulted lower than the MSC group, in both FN-PAM-VEGF
and VEGF-A. Yet the phospho-PKCe level was higher in VEGF-A
than FN-PAM-VEGF group. On the contrary, after treatments phos-
pho-ERK 1/2 levels were greatly and similarly increased in both
VEGF-A and FN-PAM-VEGF groups (Middle Panels). The analysis of
ERK1/2 showed an increase for phospho/total ratio in VEGF group
only.
Figure 10 shows that after 3-days of treatment, Bcl-2, a marker of
anti-apoptotic activity involved in the survival mechanisms, was pre-
served by FN-PAM-VEGF and decreased by free VEGF-A treatment.
Analysis after H/R
Figures 11 and 12 show the studied markers after H/R. Also in these
figures (A) MSC control group, (B) MSC treated with FN-PAM-VEGF,
and (C) MSC treated with free-VEGF-A.
Starting from different levels of total kinases, after H/R phospho-
Akt and phospho-ERK 1/2 levels were greatly and similarly increased
in VEGF-A group only, whereas phospho-PKCe abundances were
unchanged by treatment with VEGF-A or FN-PAM-VEGF (Fig. 11). In
particular, the analysis for Akt (Top Panels) evidenced a increased
phospho/total ratio of Akt in FN-PAM-VEGF and in VEGF-A groups.
The analysis of ERK1/2 (Middle Panels) showed an increase for phos-
pho/total ratio in VEGF-A group only. The analysis for PKCe (Bottom
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Panels) evidenced an unchanged phospho/total ratio in both FN-PAM-
VEGF and VEGF-A.
Figure 12 shows that after H/R, cleaved Caspase-3, a marker of
apoptosis, was significantly lower in FN-PAM-VEGF group.
Discussion
The major new finding in this study is that sustained VEGF-A release
by FN-PAM-VEGF induces a greater resistance of MSCs to H/R,
whereas free VEGF-A induces a greater increase in MSC proliferation
in normoxia.
Accordingly Akt and PKCe are more phosphorylated/activated by
free VEGF-A than by FN-PAM-VEGF, whereas MSCs treated with FN-
PAM-VEGF show a higher level of the anti-apoptotic factor Bcl-2 with
respect to VEGF-A only. Although PKCe may induce Bcl-2 biosynthe-
sis, the most important action of this kinase is to stimulate prolifera-
tion. The increased amount of Bcl-2 due to FN-PAM-VEGF could also
be attributed to the presence of fibronectin which is known to promote
cell survival viamultiple effects, including Bcl-2 over-expression [42].
Our results on proliferative mediators and anti-apoptotic agents
corroborate the different effects of the two modalities of VEGF-A
application (free VEGF-A versus FN-PAM-VEGF) on cell proliferation
in normoxia and cell survival in hypoxia. Difference may be due to dif-
ferent timing of exposure to VEGF-A and kinases responses. In fact,
while both treatment and pre-treatment with free VEGF-A increase cell
proliferation more than FN-PAM-VEGF in normoxia, only pre-treat-
ment with FN-PAM-VEGF limits cell mortality after H/R. Since pro-
proliferative kinases were more rapidly activated by free VEGF-A than
FN-PAM-VEGF, we observe an enhanced proliferation with free VEGF-
A. Moreover, after 3 days of treatment the levels of phospho-ERK 1/2
– involved in the survival mechanisms – are similarly increased by
both treatments (free VEGF-A and FN-PAM-VEGF), and the anti-apop-
totic activity (e.g. Bcl-2) is better preserved by FN-PAM-VEGF than
free VEGF-A; thus, we suggest that these factors may be responsible
of the greater resistance to hypoxia challenging by MSCs pre-treated
with FN-PAM-VEGF.
Although some of the studied factors may exert both pro-
proliferative and anti-apoptotic effects (e.g. phospho-Akt), we can
observe that Blc-2, a specific anti-apoptotic agent, is increased by
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Fig. 7Western blot analysis of Akt (top panels), ERK1/2 (middle panels), and PKCe (bottom panels) after 30-min. (A) MSC control group (B) MSC
treated with FN-PAM-VEGF, and (C) MSC treated with free-VEGF-A. The panels on the left are normalized phospho/total kinase ratios. The central
panels are representative bands of total and phospho-kinases. The panels on the right show the normalized mean values of phospho-enzyme only.
We normalized the expression of total kinases and phospho-kinases for each condition to its matched loading control b actin and then where nor-
malized with respect to the mean values of MSCs kept under standard conditions for 30-min. After 30-min. treatment, only free-VEGF-A induces an
increase in phosphorylation of Akt, ERK1/2 and PKCe. *P < 0.05 respect to MSC control group; n = 3 for each condition.
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FN-PAM-VEGF, whereas agents with proliferative properties, such as
phospho-Akt and phospho-PKCe, are higher when VEGF-A is given
alone. The phospho-ERK 1/2 is similarly increased by both treat-
ments; whereas ERK 1/2 shows an increase in phospho/total ratio in
VEGF-A group only.
These results suggest a stronger anti-apoptotic activity by FN-
PAM-VEGF with respect to VEGF-A alone. Yet VEGF-A stimulates
mainly proliferative agents. Therefore in normoxia the cell number is
increased greatly by VEGF-A; whereas in H/R cell death is mainly lim-
ited by FN-PAM-VEGF. Moreover, as said, we should consider that
although Akt is both a proliferative and an anti-apoptotic agent, Bcl-2
is an anti-apoptotic factor specifically activated against H/R [43]. In
fact, after H/R in FN-PAM-VEGF group phospho-Akt/Akt ratio is
increased and cleaved Caspase-3 is reduced. Therefore, it is likely that
VEGF-A alone promotes proliferation in normoxia (via Akt phosphory-
lation) thus increasing the number of viable cells. Yet FN-PAM-VEGF
increases cell survival by reducing apoptosis (via Bcl-2 preservation
in normoxia, as well as via Akt ratio increase and cleaved Caspase-3
reduction after H/R).
The efficiency of the transplanted MSCs is limited by several
factors, including a hostile environment such as that occurring in
inflammation, reoxygenated or aging tissue and the lack of growth
factors [7]. Several approaches have been suggested to overcome
these hurdles. Strategies using pre-treated cells with MSC co-cul-
ture or co-transplantation with other cells have been investigated
to improve cell survival in hypoxic conditions. Some studies have
suggested that endothelial cells would participate to cell survival,
proliferation as well as vascularization in such conditions [44–46].
For example, this effect may be related to paracrine activity of HU-
VEC on MSCs, as recently reported in vitro [44, 47]. A dual cell
transplantation of HUVEC with MSCs has been tested also in vivo,
with an improvement of the differentiation of MSCs in smooth
muscle cells and with subsequent improvement of vasculogenesis
and post-ischemic cardiac function [46, 48]. However, studies have
on the contrary reported the paracrine effect of MSCs on endothe-
lial cells in vitro under hypoxic condition [45, 49] but also the
effect of the contemporary transplantation of MSCs and endothelial
cells in vivo using ischemic models [46, 48, 50]. Indeed, the secre-
tion of different cytokines by MSCs is well known, and among
them VEGFs are well documented [22]. Despite these beneficial
effects, VEGFs produced by cells is not enough to promote a suffi-
cient protection to the transplanted MSCs; therefore in situ delivery
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Fig. 8Western blot analysis of Akt (top panels), ERK1/2 (middle panels), and PKCe (bottom panels) after 1-day. (A) MSC control group (B) MSC
treated with FN-PAM-VEGF, and (C) MSC treated with free-VEGF-A. The panels on the left are normalized phospho/total kinase ratios. The central
panels are representative bands of total and phospho-kinases. The panels on the right show the normalized mean values of phospho-enzyme only.
We normalized the expression of total kinases and phospho-kinases for each condition to its matched loading control b actin and then where nor-
malized with respect to the mean values of MSCs kept under standard conditions for 1-day. Only FN-PAM-VEGF induces a significant reduction in
phospho/total Akt ratio and phospho Akt level. *P < 0.05 respect to MSC control group; n = 3 for each condition.
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of exogenous VEGFs has been proposed to improve cell survival
[23, 51, 52].
Another feasible approach is the development of biopolymer-
based growth factor delivery for tissue repair, which may be beneficial
even in the case of reduced availability of stem cell to implant. Several
kinds of scaffolds composed of synthetic or natural polymers have
been tested with different experimental models in preclinical and clini-
cal studies. PAMs have been developed which combine, in an adapt-
able and simple device, in situ controlled drug delivery and
implantation of cell adhered onto biomaterials-based scaffolds. The
PAMs used in the present study are biocompatible and biodegradable
microspheres made of poly (D,L-lactide-co-glycolide acid (PLGA))
with a biomimetic surface of ECM molecules supplying a three-
dimensional structure for the cell both in vitro and in vivo after
transplantation. They may also be engineered to release a therapeutic
factor in prorogated manner [53]. Therefore these combined parame-
ters may promote or maintain cell survival, differentiation and integra-
tion in the host tissue after complete degradation of the carrier. In
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Fig. 9Western blot analysis of Akt (top panels), ERK1/2 (middle panels), and PKCe (bottom panels) after 3-days. (A) MSC control group (B) MSC
treated with FN-PAM-VEGF, and (C) MSC treated with free-VEGF-A. The panels on the left are normalized phospho/total kinase ratios. The central
panels are representative bands of total and phospho-kinases (some of the presented bands were not juxtaposed in the original film). The panels on
the right show the normalized mean values of phospho-enzyme only. We normalized the expression of total kinases and phospho-kinases for each
condition to its matched loading control b actin and then where normalized with respect to the mean values of MSCs kept under standard condi-
tions for 3-days (MSC-3). It can be appreciated a reduced Akt phospho/total ratio in FN-PAM-VEGF, an increased ERK1/2 phospho/total ratio in
VEGF-A, and an increased phospho/total ratio of PKCe in both FN-PAM-VEGF and VEGF-A groups. *P < 0.05 respect to MSC control group;
**P < 0.001 respect to MSC control group. n = 4 for each condition.
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Fig. 10 Representative blots and mean levels of the anti-apoptotic fac-
tor, Bcl-2 after 3-days treatment with active factors (free-VEGF-A and
FN-PAM-VEGF). (A) MSC control group (B) MSC treated with FN-PAM-
VEGF, and (C) MSC treated with free-VEGF-A. We normalized the
expression of Bcl-2 for each condition to its matched loading control b
actin and then where normalized with respect to the mean values of
MSC-3. It can be appreciated an increase of Bcl-2 in FN-PAM-VEGF and
a decrease in VEGF-A group. *P < 0.05 respect to MSC-3; **P < 0.001
respect to MSC-3. n = 4 for each condition.
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particular, adhesion to structural glycoproteins of the ECM seems to
be necessary for cell survival and fibronectin is considered as a pro-
tective factor for many adherent cells [54]. Moreover, it has been
recently suggested a novel pro-survival pathway involving integrin
receptors and proteins of Bcl-2 family which can be stimulated by
fibronectin [42]. Thus, we cannot rule out that the differences
observed between VEGF-A and FN-PAM-VEGF groups inherent their
effects on MSC survival can be due, at least in part, to the interaction
of VEGF-A with fibronectin.
VEGF-A production is a crucial component of stem cell-mediated
cardioprotection as evidenced by a reduction in post-ischemic
myocardial functional recovery following intracoronary infusion of
MSCs with targeted VEGF-A suppression using siRNA [51]. Here
using either VEGF-A alone or in combination with FN-PAMs (FN-PAM-
VEGF) we observed an enhanced proliferation of MSCs in normoxia.
However, VEGF-A is more effective than FN-PAM-VEGF in inducing
proliferation. On the other hand, in hypoxic conditions FN-PAM-VEGF
was more protective than VEGF-A against H/R challenging. Differ-
ences between free VEGF-A and FN-PAM-VEGF may be due also to
the VEGF-A kinetics of release elicited by the FN-PAM (see Fig. 3).
Since it has been underlined that reduced proliferation might favor
stem cell differentiation, whereas highly proliferating stem cells hardly
differentiate [55, 56], we suggest that functionalized FN-PAM induc-
ing a limited proliferation and an increased resistance to hypoxia/
reoxygenation may be a novel approach for enhancing MSC survival
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Fig. 11Western blot analysis of Akt (top panels), ERK1/2 (middle panels), and PKCe (bottom panels) after hypoxia/reoxygenation (H/R). (A) MSC
control group (B) MSC treated with FN-PAM-VEGF, and (C) MSC treated with free-VEGF-A. The panels on the left are normalized phospho/total
kinase ratios. The central panels are representative bands of total and phospho-kinases. The panels on the right show the normalized mean values
of phospho-enzyme only. We normalized the expression of total kinases and phospho-kinases for each condition to its matched loading control b
actin and then where normalized with respect to the mean values of MSCs subjected to H/R. It can be appreciated an increased Akt phospho/total
ratio in both FN-PAM-VEGF and VEGF-A groups, an increased ERK1/2 phospho/total ratio in VEGF-A only, and an unchanged phospho/total ratio of
PKCe in both FN-PAM-VEGF and VEGF-A groups. *P < 0.05 respect to MSC control group; n = 3 for each condition.
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Fig. 12 Representative blots and mean levels of the apoptotic factor,
cleaved Caspase-3 after hypoxia/reoxygenation (H/R). (A) MSC control
group (B) MSC treated with FN-PAM-VEGF and (C) MSC treated with
free-VEGF-A. We normalized the expression of cleaved Caspase-3 for
each condition to its matched loading control b actin and then where
normalized with respect to the mean values of MSC. It can be appreci-
ated a decrease of cleaved Caspase levels in FN-PAM-VEGF group only.
*P < 0.05 respect to MSC-3. n = 3 for each condition.
ª 2012 The Authors
Journal of Cellular and Molecular Medicine Published by Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
201
J. Cell. Mol. Med. Vol 17, No 1, 2013
and differentiation and, thus, regeneration of damaged tissue. For
instance, FN-PAM-VEGF can be used when the cell loss affects the
heart, to limit heart failure [57]. In fact MSCs can differentiate into
vascular endothelial cells and cardiomyocytes and can improve heart
function even via vascular paracrine signaling effects [3, 4, 58, 59].
Although here we do not report data about the effects of PAM
and/or VEGF-A for periods longer than a week or in vivo, toxicity
and lack of effectiveness are not of concern. In fact, the angiogenic
properties of VEGF-A slowly released by microspheres have been
demonstrated to promote localized neovascularization at the subcu-
taneous site in the rat [e.g. 29]. Moreover, our group has con-
firmed in experimental studies both the ability of FN-PAM-VEGF to
stimulate the functionality of endothelial progenitor cells in vitro
[60] and the biocompatibility or lack of toxicity of PAM in the brain
in vivo [27, 61]. Yet, these PLGA microspheres, which are biode-
gradable polymer fully metabolized by the organism, have been
used in clinical trials for treating gliomas [61]. Finally, PLGA
implantable devices are approved by the FDA and PLGA sutures are
widely used in surgery.
Conclusions
Our data suggest that in vitro treatment with free VEGF-A enhances
MSC proliferation, most likely trough the rapid activation of pro-sur-
vival kinases and persistence of ERK 1/2 pathway. Yet, controlled
release of VEGF-A from FN-PAM-VEGF limits mainly MSC death via
both ERK 1/2 and Bcl-2 mechanisms, thus enhancing MSC survival in
post-hypoxic environment.
Our data are in line with the viewpoint that in therapies with cell
transplantation are needed approaches adapted to the varying con-
ditions. We suggest that the use of FN-PAM complexed with growth
factors could be considered a new approach to improve MSC sur-
vival in hostile environments such as inflammatory and post-ische-
mic tissue. If confirmed in an appropriate pre-clinical model, this
approach may be envisaged for future clinical studies on cardiac
tissue regeneration.
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